Zhigang Yang, DO
General Practice · New York, NYNPI 1528345394
Payments from drug & device makers
Across 310 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- GSK$693
- Amgen$686
- Esperion Therapeutics, Inc.$610
- Amarin Pharma, Inc.$578
- plus $4K from 19 others
Across 1 payment — averaging $16.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$16
What the payments were for
- Food & beverage$8,885100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 81 | $1,669 |
| AbbVie(2 entities) | 33 | $1,180 |
| GSK | 27 | $693 |
| Amgen | 31 | $686 |
| Esperion Therapeutics, Inc. | 12 | $610 |
| Amarin Pharma, Inc. | 26 | $578 |
| AstraZeneca | 12 | $515 |
| Ironwood Pharmaceuticals, Inc | 23 | $443 |
| SPR Therapeutics, Inc | 4 | $403 |
| Novo Nordisk | 9 | $271 |
| Johnson & Johnson(2 entities) | 8 | $251 |
| Nevro Corp. | 2 | $228 |
| Merck | 13 | $200 |
| IBSA Pharma Inc. | 4 | $173 |
| Boehringer Ingelheim | 3 | $162 |
| Gilead | 2 | $147 |
| Angiodynamics, Inc. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 5 | $117 |
| Boston Scientific | 1 | $116 |
| Aimmune Therapeutics, Inc. | 4 | $91 |
| Abbott | 1 | $80 |
| Pfizer | 3 | $77 |
| Kowa Pharmaceuticals America, Inc. | 3 | $62 |
| Lilly USA, LLC | 1 | $25 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,920 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 949 | $423,568 |
| Diclofenac Epolamine | 450 | $256,018 |
| LinzessLinaclotide | 215 | $116,911 |
| Diclofenac Sodium | 220 | $108,240 |
| JanuviaSitagliptin Phosphate | 147 | $99,657 |
| FarxigaDapagliflozin Propanediol | 104 | $65,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $58,494 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 197 | $55,898 |
| JardianceEmpagliflozin | 78 | $52,330 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 78 | $52,238 |
| CreonLipase/Protease/Amylase | 56 | $50,335 |
| NexletolBempedoic Acid | 114 | $48,980 |
| ProliaDenosumab | 28 | $48,444 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 93 | $48,092 |
| XifaxanRifaximin | 20 | $46,460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis | $1,180 | $193,192312 claims |
| MerckJanuvia, Janumet Xr, Janumet | $200 | $174,483283 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $515 | $128,823194 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $1,669 | $77,92875 claims |
| PfizerAbrysvo, Eliquis | $77 | $77,343221 claims |
| Novo NordiskOzempic, Rybelsus | $271 | $71,56661 claims |
| Boehringer IngelheimJardiance, Tradjenta | $162 | $69,147111 claims |
| GSKTrelegy Ellipta, Shingrix | $693 | $66,381130 claims |
| Esperion Therapeutics, Inc.Nexletol | $610 | $48,980114 claims |
| AmgenProlia | $686 | $48,44428 claims |
| GileadVemlidy, Viread | $147 | $47,41137 claims |
| Johnson & JohnsonXarelto | $251 | $44,57479 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.
Other general practice in New York
- Alejandra Gonzalez-DuarteNew York$519K
- Ronnie MyersNew York$464K
- Laila AkhlaghiNew York$52K
- Caroline CampbellNew York$50K
- Vezire SarakNew York$39K
- Yohan KimNew York$38K
- Christine SkordelesNew York$32K
- Jose GorisNew York$23K
- Bruce YaffeNew York$22K
- Joseph PantaleoNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.